News | August 16, 2021
Orchid Pharma reports net loss of Rs 30.90 cr in Q1FY22
EPS for the period at Rs. (7.57)
EPS for the period at Rs. (7.57)
The hospital chain aggressively embarks on digitisation and is e-health ready
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
EPS at Rs 32.19
Substantial reduction in losses
Income declines marginally
The company has strong product launches both in India and overseas
The company has tied up with OrbiMed as a financial partner for global reach
The profits were bolstered by the Boehringer Ingelheim MEK program income
Subscribe To Our Newsletter & Stay Updated
